SCHEMBL9894514

SCHEMBL9894514

CC=C(C(=O)OC)c1ccccc1COc1ccc(/C(C)=N\OCCC)cc1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 7/20 0.48
MAOB P27338 6/20 0.41
MAOA P21397 2/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
PTPRC P08575 1/20 0.37
PTPN1 P18031 1/20 0.37
PARP15 Q460N3 1/20 0.37
PARP14 Q460N5 1/20 0.37
PARP10 Q53GL7 1/20 0.37
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894515 0.92 HIF1A (0.46) HIF1AMAOBMAOAPPARGPPARA
SCHEMBL9894511 0.92 HIF1A (0.46) HIF1AMAOBMAOAPPARGPPARA
SCHEMBL9894513 0.92 HIF1A (0.46) HIF1AMAOBMAOAPPARGPPARA
SCHEMBL9895439 0.89 HIF1A (0.46) HIF1AMAOBPPARGPPARAKDM4E
SCHEMBL9895316 0.88 HIF1A (0.49) HIF1AMAOBKDM4ESMN1; SMN2L3MBTL1
SCHEMBL9894838 0.86 PPARG (0.44) HIF1APPARGPPARAKDM4ESMN1; SMN2
SCHEMBL9894369 0.86 HIF1A (0.48) HIF1APPARGPPARAKDM4E
SCHEMBL9894795 0.85 HRH3 (0.45) HIF1AKDM4E
SCHEMBL9895042 0.83 HIF1A (0.39) HIF1APPARGPPARA
SCHEMBL9895438 0.82 HIF1A (0.44) HIF1AMAOBPPARGPPARAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US claimed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP claimed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US claimed
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US disclosed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP disclosed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME HIF1A, HIF1AN, EGLN3 HIF1A 1/4885MAOB 2441/4885MAOA 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.